Cited clinician table.
Sort products by name, status, or year. Every row’s claim links to a source on the record.
| Regions on this atlas | Cited claim | |||
|---|---|---|---|---|
| Aducanumab | withdrawn | — | — | Aducanumab was an amyloid antibody whose US Alzheimer’s indication was later withdrawn. It is historical context, not a current option. FDA withdrawn accelerated approvals |
| Brexpiprazole | approved | US | 2023 | Brexpiprazole has a US indication for agitation in Alzheimer’s dementia after other causes are considered. Antipsychotics increase mortality in elderly people with dementia-related psychosis. FDA agitation approval |
| Donanemab | approved | US, JP, UK, EU, CN, AU | 2025 | Donanemab is a monthly infused antibody for early Alzheimer’s disease after amyloid confirmation, with the same ARIA monitoring theme as other amyloid antibodies. FDA Kisunla approval |
| Donepezil | approved | US, EU, UK, JP, CN, AU | 1999 | Donepezil is a tablet used for cognitive symptoms in Alzheimer’s disease. It may help some people a little. It does not slow the disease itself. FDA label index |
| Galantamine | approved | US, EU, UK, JP, CN, AU | 2011 | Galantamine is a tablet for mild-to-moderate dementia of the Alzheimer’s type. It is not approved for vascular, frontotemporal, or Lewy body dementia. FDA label index |
| Lecanemab | approved | US, JP, CN, UK, EU, AU | 2025 | Lecanemab is an infused antibody for early Alzheimer’s disease after amyloid is confirmed. It can cause brain swelling or bleeding on MRI and is not a cure. FDA traditional approval |
| Memantine | approved | US, EU, UK, JP, CN, AU | 2011 | Memantine is a tablet used in moderate-to-severe dementia of the Alzheimer’s type. It is a symptom treatment, sometimes combined with a cholinesterase inhibitor. DailyMed memantine |
| Remternetug | phase-3 | — | — | Remternetug is an investigational amyloid antibody. It is not approved. Trial eligibility is not a treatment recommendation. ClinicalTrials.gov search |
| Rivastigmine | approved | US, EU, UK, JP, CN, AU | 2011 | Rivastigmine is used for Alzheimer’s dementia and has a US indication for dementia associated with Parkinson’s disease. It is a symptom treatment. Alzheimer’s Association: medicines for cognition |